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Abstract: In the last decade, a new armamentarium of immune-based therapies have been 
developed and tested in patients with multiple sclerosis. Some of these therapies are showing 
a high level of efficacy, with an acceptable adverse effect profile. Because present therapies 
have significant limitations in slowing disease progression, require injections, are sometimes 
associated with significant side effects of immunosuppression, and do little to reverse disabil-
ity, identifying more effective treatments is an important goal for clinical research in multiple 
sclerosis. However, in order to improve our current approach to disease-modifying therapies, 
it is imperative to promote the development of individualized therapy strategies.
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Introduction
Recent advances in our understanding of the immunopathogenesis of multiple sclerosis 
(MS) have generated the development of novel and promising neurotherapeutic strate-
gies. This review summarizes the most updated data from recent Phase II/III clinical 
trials evaluating the clinical efficacy and safety of promising therapeutic interventions 
in MS patients (Table 1). Other potential side effects may come to light with more 
patients studied and greater use of these drugs.
Lymphocyte-targeted therapy
Cladribine
Cladribine is a purine nucleoside analogue that produces lymphotoxic effects when 
incorporated into the DNA of resting and dividing cells with high deoxycytidine kinase 
activity (lymphocytes and monocytes), and subsequent interruption of DNA replica-
tion, DNA damage, and cell death.1 In addition to its lymphotoxic effects, cladribine 
possesses epigenetic properties, by inhibiting S-adenosyl homocysteine hydrolase 
and DNA methylation.2 It received FDA approval in the 1980s for treatment of hairy 
cell leukemia.
Parenteral cladribine (total dose 2.8 mg/kg) significantly reduced the number 
and volume of T1 gadolinium-enhancing lesions, accumulation of T2 lesion volume, 
relapse rate, and disability progression in patients with progressive and relapsing 
forms of MS.3–5 A dose-dependent increase in adverse events was observed, leading 
to selection of low doses for use in an ongoing clinical development program of an 
oral tablet formulation.Journal of Inflammation Research 2010:3 54
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A recent placebo-controlled Phase III trial using oral 
cladribine in patients with relapsing-remitting MS (RRMS), 
showed a 58% reduction in annualized relapse rates 
(3.5 mg/kg daily for four to five days, with two courses in the 
first year) at two years compared with placebo. In addition, 
80% of patients remained relapse-free, compared with 61% 
of patients in the placebo group (P  0.001 for both dose 
regimens). Patients in the active drug group experienced a 
30% reduction in the risk of disability progression relative 
to patients in the control group.6 Adverse events included 
headaches, nasopharyngitis, upper respiratory tract infec-
tions, and nausea. Lymphopenia occurred more frequently 
in the active drug group (22%). Of the patients treated with 
cladribine tablets, 2.3% reported herpes zoster infections, 
although these were localized to the skin and were responsive 
to preventative treatment. A Phase III trial investigating oral 
cladribine in clinically isolated syndrome and a Phase IIb 
trial of combination therapy with interferon (IFN) β-1a is 
currently underway with an estimated date for completion 
of February 2010. Cladribine has the potential to be the first 
orally administered disease-modifying therapy available for 
patients with relapsing MS. As of December 2009 the FDA 
has not accepted Serono’s approval application.
Alemtuzumab
Alemtuzumab is a humanized monoclonal antibody directed 
against CD52, a cell surface receptor expressed on lympho-
cytes, natural killer cells, monocytes, and macrophages. 
Alemtuzumab binds to B- and T- lymphocytes, resulting in 
antibody-dependent cell lysis, and subsequent elimination 
from the bone marrow and blood, with the effect lasting up 
to 16 months. Interestingly, the capacity of the immune cells 
Table 1 Selected emerging MS therapies
Lymphocyte-targeted 
therapy
Mechanism of action  Route/Dose  Results  Status  AEDs 
Cladribine Purine nucleoside 
analog
Oral (3.5 and 
5.25 mg/kg 
total dose)
58% ↓ RR, 43% 
disease free
Phase III HZV, lymphopenia, HA, 
nasopharyngitis, 
lymphopenia
Alemtuzumab Anti-CD52 IV 12 mg dose/y 75% ↓ SAD (12 mg dose), 
74% ↓ RR
Phase III ITP (3 pts), Graves  
disease (20%)
Daclizumab Anti-CD25/anti-IL2 SQ 2 mg/kg (Q2w) 72% ↓ CEL in 
RRMS patients
Phase II Skin rash, chest  
discomfort, headaches, 
lymphopenia
Rituximab Anti-CD20 IV (1 gram 
dose, Q2w, 3 2)
91% ↓ CEL in RRMS Phase II Infusion reaction, allergies
CTLA4Ig Prevents T cell 
activation
IV (2, 10.0, 20.0, or  
35.0 mg/kg)
No significant changes Phase I Lymphadenopathy, 
urinary tract infections, 
headaches, blurred vision, 
and upper respiratory 
tract infections
Immune- 
sequestration
Fingolimod Sphingosine-1- 
phosphate (S1P) 
analog
Oral (1.25 and 
5 mg)
80% ↓ CEL, 50% ↓ RR Phase III Bradycardia, nasopharyn-
gitis, dyspnea,   headaches, 
diarrhea, nausea, 
encephalitis, skin cancer
SB-683699 Alpha-4 integrin 
antagonist
Oral (150–1200 mg  
Twice Daily)
No data available Phase II No data available
Unspecific  
immunosupression
Laquinimod Antiinflammatory Oral 0.6 mg/d 40% ↓ CEL Phase III LFT elevation,  
Budd Chiari
Fumaric acid (BG12) Antiinflammatory/ 
Neuroprotective
Oral (120–240 mg  
TID)
69% ↓ CEL Phase III Diarrhea, cramps, nausea 
and flushing
Teriflunomide 
 
Inhibition of immune 
cell proliferation 
Oral (7 and 14 mg  
dose) 
61% ↓ CEL 
 
Phase II 
 
Nasopharyngitis, alopecia, 
nausea, limb pain,  
diarrhea, and arthralgia
Abbreviations: RR, relapse rate; HZV, herpes zoster virus; HA, headaches; IV, intravenous; SAD, sustained acumulation of disability; ITP, immune thrombocytopenic purpura; 
SQ, subcutaneous; CEL, contrast enhancing MRI lesions; RRMS, relapsing remitting Multiple Sclerosis; LFT, liver function test.Journal of Inflammation Research 2010:3 55
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to regenerate remains intact after repetitive drug cycles, but 
immature forms of B-cells (transitional type I cells) possibly 
driven by high B-cell activation factor levels are seen early in 
the course of immune reconstitution. This event could explain 
the association and development of antibody-mediated 
autoimmune disorders seen in the course of alemtuzumab 
therapy. Alemtuzumab is currently FDA-approved to treat 
B-cell chronic lymphocytic leukemia.
Studies of alemtuzumab in the treatment of patients 
with relapsing-remitting (RR) and secondary progressive 
MS (SPMS) have suggested efficacy in the suppression of 
annualized relapse rates, but with variable results in prevent-
ing progression of disability, depending on stages of the 
disease. In a recent Phase II randomized blinded clinical trial 
of intravenous (IV) alemtuzumab at 12 mg per day or 24 mg 
per day for five consecutive days during the first month and 
on three consecutive days at 12 and 24 months, alemtuzumab 
significantly reduced the rate of sustained accumulation of 
disability by 71%, with a 74% reduction in the annualized 
rate of relapse compared with IFN β-1a in patients with 
early RRMS. Over 80% of patients receiving alemtuzumab 
remained relapse-free at 36 months. Reduction in T2 lesion 
volume and total brain volume analysis was greater in the 
alemtuzumab group. Adverse events in the alemtuzumab 
group included autoimmune thyroid disorders and thrombo-
cytopenic purpura as well as infections. About one-third of 
patients develop antibodies against the thyrotropin receptor 
and subsequently develop autoimmune hyperthyroidism.7 
Currently there are two Phase III trials comparing two annual 
cycles of IV alemtuzumab with three times weekly IFN β-1a 
in treatment-naïve patients with RRMS (CARE-MS1 and 
CARE MS-2). These studies are expected to be completed 
in 2011 or 2012.
Rituximab
Rituximab is a chimeric antibody directed against human 
CD20 phosphoprotein present on all B-cell lineages except 
for stem cells, pro-B cells, and plasma cells. Rituximab acts 
by binding to B-cell lymphocytes, initiating a cascade of 
events that leads to B-cell lysis and subsequent depletion. 
The benefit of B-cell depletion in controlling the course of the 
disease supports the recently recognized active role of B-cells 
in the pathogenesis of MS. The standard dose of rituximab is 
375 mg/m² given weekly for four weeks, or a fixed dose of 
2 g divided into two infusions of 1 g each two weeks apart. 
Following an IV administration of 2 g of rituximab, CD20 
positive B-cells are rapidly depleted and remain undetectable 
for up to six months longer.
Rituximab has shown efficacy in the treatment of patients 
with RRMS. A recently completed randomized clinical 
trial using a standard dose of rituximab in RRMS patients 
demonstrated a 91% reduction in the number of gadolinium-
enhancing lesions on (magnetic resonance imaging (MRI) 
scans, as well as a significant reduction in the number of 
clinical relapses. Mild infusion-related complications were 
seen in most patients, but serious adverse reactions were rare.8 
In a recent trial of patients with primary progressive multiple 
sclerosis (PPMS), rituximab appeared to have efficacy only 
in young patients with signs of active inflammation on MRI 
scans.9 Five cases of progressive multifocal leukoencepha-
lopathy have been recently reported in patients receiving 
rituximab for the treatment of rheumatoid arthritis and sys-
temic lupus erythematosus. However, these patients were 
receiving other immunosuppresants.
Ocrelizumab, a humanized monoclonal antibody against 
human CD20, is currently under investigation in a Phase II 
trial evaluating its efficacy and safety in patients with RRMS. 
The estimated date of completion for this trial is 2012.10 
Given the functional similarities between rituximab and 
ocrelizumamb, it is unclear which of these will be developed 
for use in MS.
Daclizumab
Daclizumab is a humanized mouse monoclonal antibody that 
binds to the alpha-subunit of the interleukin (IL)-2 receptor. 
This receptor is present on activated T- and B-cells but not 
on natural killer (NK) cells, and is crucial for T-cell prolifera-
tion and activation. The clinical benefit of daclizumab has 
been linked to significant expansion of immunoregulatory 
CD56 NK cells, and subsequent downregulation of adaptive 
T-cell responses (CD4 and CD8 positive T-cells).11 In an initial 
open-label study with IV daclizumab 1 mg/kg, five patients 
with SPMS and six patients with RRMS demonstrated a 
decrease in number of contrast-enhancing lesions by 78% and 
in relapse rate by 81% compared with baseline.12 A recent 
open-label Phase II trial using subcutaneous daclizumab 
2 mg/kg in MS patients with inadequate response to IFN β 
therapy, demonstrated a 72% reduction in the number of new 
or enlarged contrast-enhancing lesions at week 24 compared 
with patients receiving IFN β alone. Because Type I IFN is 
also known to enhance NK cell function, the question of 
possible synergism between IFN and daclizumab therapy is 
raised.13 Skin rash, chest discomfort, headaches, lymphope-
nia, generalized lymphadenopathy, and transient elevation of 
liver function tests and bilirubin levels have been reported. 
Daclizumab is already in clinical use to prevent rejection of Journal of Inflammation Research 2010:3 56
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kidney transplants. A multicenter Phase II trial investigating 
a subcutaneous formulation of daclizumab monotherapy is 
ongoing.
CTLA-4 Ig
CTLA-4Ig is a chimeric fusion protein that prevents T-cell 
activation by binding the B7-1 and B7-2 costimulatory mol-
ecules on antigen-presenting cells. A recent Phase I clinical 
trial showed that IV administration of CTLA-4Ig was well 
tolerated in patients with MS, and most adverse events were 
rated as mild. Lymphadenopathy, urinary tract infections, 
headaches, blurred vision, and upper respiratory tract infec-
tions were most frequently reported. Immunologic assess-
ment of the patients showed a reduction in myelin basic 
protein proliferation within two months of infusion and 
decreased IFN-γ production by myelin basic protein-specific 
lines. No significant changes in clinical or MRI parameters 
were observed during the study.14
Immune sequestration
Fingolimod
Fingolimod (FTY720), an oral sphingosine-1-phosphate 
(S1P) analog, acts as a partial agonist on S1P receptors, 
inducing internalization of the S1P receptor, thereby block-
ing the mechanism necessary for lymphocytes to migrate out 
of secondary lymphoid structures. Fingolimod is associated 
with significant decreases in circulating T- and B-cells, 
particularly in central and naïve memory T-cells, with lesser 
reductions on effector memory T-cells.15 As a result of its 
lipophilic nature, fingolimod crosses the blood-brain barrier 
and possibly also downmodulates S1P1 in neural cells and 
astrocytes, thereby reducing astrogliosis, a phenomenon 
associated with neurodegeneration in MS.16
A recent multicenter, randomized, double-blind, placebo-
controlled Phase III study with extension in RRMS patients 
demonstrated that oral fingolimod at doses of 1.25 and 5 mg, 
reduced the number of new focal inflammatory lesions by 80% 
and relapse rates by 50% compared with placebo.9 Over two 
years, the average annualised relapse rate in patients receiv-
ing fingolimod was 0.21, 75%–77% of patients remained 
free of relapses, and 80% remained free of new enhancing 
MRI lesions. In addition, patients initially receiving placebo 
showed a marked improvement in clinical parameters of MS 
after switching to fingolimod in the extension study, which was 
sustained at month 24. Adverse reactions included bradycardia, 
nasopharyngitis, dyspnea, headaches, diarrhea, and nausea. 
Initial bradycardia was seen more frequently in the 5 mg dose 
group. Three cases of basal cell carcinoma, three of squamous 
cell carcinoma, and one of melanoma were reported. Two 
fatalities occurred during the trial, and were associated with 
chicken pox and herpes virus infection. In addition, a single 
case of hemorrhagic encephalitis was reported but with an 
unclear causal relationship. Ongoing Phase III trials comparing 
the safety and efficacy of oral fingolimod 0.5 mg and 1.25 mg 
with IFN β-1a will soon yield results.17
SB-683699
SB-683699 is an oral medication that is thought to inhibit 
leukocyte trafficking across the blood-brain barrier by 
antagonism of alpha-4 integrins. A Phase II trial was recently 
completed in patients with RRMS evaluating the safety and 
efficacy of SB-683699 (150–1200 mg twice daily) in the 
development of MRI-confirmed new brain lesions at six 
months. Data from that trial will be available soon.18
Non-specific immune modulation
Laquinimod
Laquinimod (quinoline-3-carboxamid) is a once-daily, orally 
administered immunomodulatory compound that is being 
developed as a disease-modifying treatment for RRMS. The 
anti-inflammatory properties of laquinimod are thought to 
be secondary to downregulation of major histocompatibility 
complex Class II gene transcription factors, stimulation of 
neurotrophin-3, neurotrophin-4 and brain-derived neuro-
trophic factor, activation of the anti-inflammatory IL-4 
pathway in CD4+ cells, promotion of apoptosis in CD8+ and 
B-cells, and suppression of the metabolic activity of CD14+ 
and NK cells. As a consequence, there is a cytokine balance in 
favor of anti-inflammatory T-helper (Th)-2/Th-3 cytokines, 
with suppression of proinflammatory and cytokine-related 
genes. A Phase IIb study in 306 patients demonstrated that 
an oral daily 0.6 mg dose of laquinimod significantly reduced 
MRI disease activity by a median of 60% versus placebo 
in RRMS patients. The majority of the patients that have 
participated in this trial are now receiving treatment with 
laquinimod in an open-label extension trial.19 An ongoing 
Phase III trial is currently evaluating the efficacy of laquini-
mod 0.6 mg daily in patients with RRMS, with an estimated 
completion date of 2010.20
Laquinimod appears to be well tolerated, with only 
transient and dose-dependent increases in liver enzymes. 
A case of Budd-Chiari syndrome occurred after one month 
of exposure in a patient with underlying hypercoagulability. 
Unlike its precursor substance, linomide, no cases of serositis 
or myocardial infarction have been reported so far in patients 
receiving laquinimod.Journal of Inflammation Research 2010:3 57
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BG00012
BG00012 is an oral formulation of dimethyl fumarate that 
may exert a combination of anti-inflammatory and neuropro-
tective biological effects. Although its exact mechanism of 
action is not known, BG00012 is thought to inhibit immune 
cells by stimulating the expression of anti-  inflammatory 
cytokines, such as IL-10, IL-4, and IL-5. Hence, it is thought 
that dimethyl fumarate can induce a shift from a Th-1 
(pro-  inflammatory) to a Th-2 (anti-inflammatory) T-cell 
response.21 In addition, BG00012 may have a neuroprotec-
tive therapeutic effect by inducing Phase II detoxification 
genes and upregulation of the Phase II detoxification enzyme, 
NAD(P)H:quinone oxidoreductase-1.22
A previous multicenter, controlled clinical trial of oral 
BG00012 involving 257 people with RRMS receiving 
various doses of BG00012 capsules or placebo showed a 
dose-dependent reduction in active inflammation on MRI 
scans.23 Tolerability was good overall, with adverse events, 
including abdominal pain and flushing, more commonly 
occurring in the active treatment group. Two Phase III trials 
are currently ongoing evaluating if BG00012 is effective in 
reducing the proportion of relapses, decreasing the number 
of brain lesions, and slowing time to progression (DEFINE 
and CONFIRM). The estimated completion date for both 
studies is December 2010.
Teriflunomide
Teriflunomide is an inhibitor of mitochondrial dihydroorotate 
dehydrogenase, an enzyme critically involved in pyrimidine 
synthesis. Because activated lymphocytes largely depend 
on de novo pyrimidine synthesis, pyrimidine depletion 
might result in inhibition of immune-cell proliferation.24 
There is some evidence from in vitro studies suggesting 
that   teriflunomide induces Th-2-mediated anti-inflammatory 
cytokine activation.
Oral teriflunomide was tested in a randomized, double-
blind, placebo-controlled Phase II study. Patients with 
relapsing forms of MS were randomized to receive pla-
cebo, teriflunomide 7 mg or 14 mg a day for 36 weeks. 
Teriflunomide demonstrated a dose-dependent reduction 
in the number of T1-enhancing lesions. Teriflunomide was 
generally safe and well tolerated. Adverse effects included 
nasopharyngitis, alopecia, nausea, limb pain, diarrhea, 
and arthralgia. Hepatic necrosis and pancytopenia have 
been reported in patients with rheumatoid arthritis taking 
teriflunomide.
A two-year, double-blind, placebo-controlled Phase III 
study in relapsing MS is in progress.25 The primary outcome 
measure is relapse rate. Other ongoing or planned studies of 
teriflunomide include a Phase II study of combination with 
IFN-β, a Phase II study of combination with glatiramer 
acetate, and a placebo-controlled Phase III trial in clinically 
isolated syndrome.26–28
Failed trials
Antigen-based immune therapies
Induction of tolerance by antigen-based immune therapy 
appears to be a promising strategy in the treatment of 
autoimmune disorders. Recent studies evaluating the 
administration of a myelin basic protein-derived peptide 
(MBP8298) in patients with progressive forms of MS 
suggested a benefit in disease progression by clinical 
parameters in a subgroup of patients with HLA-DR2 and 
DR4 haplotypes. Two Phase II/III trials investigating 
MBP9298 in SPMS and RRMS patients with HLA-DR2 
and four haplotypes were unfortunately negative.29,30 As of 
December 2009 there are no plans to restudy this molecule.
IL-12 and IL-23 inhibitors
IL-12 and IL-23 have been strongly implicated in the 
pathogenesis of MS. IL-23 is produced mainly by activated 
myeloid cells, and promotes and stabilizes IL-17 produc-
tion by CD4+ T-cells, with subsequent tissue inflammation. 
  Circulating mononuclear cells from patients with MS express 
increased concentrations of IL-12 and IL-23. Ustekinumab 
is a fully human monoclonal antibody against IL-12/23 p40 
that neutralises IL-12 and IL-23. A Phase II, multicentre, 
randomised, double-blind, placebo-controlled study was done 
evaluating the administration of 27 mg, 90 mg, or 180 mg 
ustekinumab every four weeks or 90 mg ustekinumab every 
eight weeks versus placebo. Unfortunately, this study did not 
demonstrate a significant benefit on formation of inflamma-
tory white matter lesions or affect clinical events in patients 
with RRMS.31
Atacicept
Atacicept is an immunoglobulin fusion protein tumor 
necrosis factor family receptor transmembrane activator, 
calcium modulator, and cyclophilin ligand interactor which 
sequesters the B-cell survival factor, a proliferation-inducing 
ligand (APRIL), and B-lymphocyte stimulator of the tumor 
necrosis factor family (BLys) and thus inhibits later stages 
of B-cell development. A recent Phase II clinical trial evalu-
ating efficacy and safety profiles in patients with MS was 
terminated because preliminary data suggested an increase 
in disease activity in patients receiving atacicept.32Journal of Inflammation Research 2010:3 58
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Remyelination and neural repair
CNS remyelination is mostly mediated by oligodendrocyte 
progenitor cells. The ability to remyelinate is in general 
incomplete and fails over time. Many environmental factors 
play an important role in promoting or inhibiting myelin 
repair and oligodendrocyte differentiation. Of these, neurite 
outgrowth inhibitor Nogo-A, and its co-receptors TROY 
and LINGO-1 have been studied in both in vitro and in vivo 
studies.33 Administration of anti-Nogo-A antibodies resulted 
in significant axonal growth in vitro and in animal models of 
spinal cord injury.34 Passive immunization with anti-Nogo-A 
antibodies in animal models of MS resulted in less demyelin-
ation and axonal damage compared with controls.35 A Phase I 
clinical open-label multicenter safety study evaluating con-
tinuous intrathecal administration of anti-Nogo-A antibody 
(ATI355) in patients with spinal cord injury is currently 
ongoing. The completion date is estimated to be November 
2010. Overexpression of LINGO-1 inhibits oligodendrocyte 
differentiation and myelination, whereas attenuation of its 
function or administration of LINGO-1 antagonist antibody 
(anti-LINGO-1) enhances oligodendrocyte differentiation 
and myelination.36,37 In vivo studies demonstrated the pres-
ence of TROY and LINGO-1 in a subpopulation of reactive 
astrocytes, macrophages, and microglia in MS brain lesions.38 
Treatment with an antibody antagonist to LINGO-1 function 
leads to functional recovery and increased integrity of axons 
in rats with experimental autoimmune encephalomyelitis 
induced by myelin-oligodendrocyte-glycoprotein.39 Stud-
ies of an anti-LINGO-1 monoclonal antibody are under 
consideration.
Cellular remyelinating strategies, involving both embry-
onic and neural stem cells, are being proposed as an elec-
tive source of brain cells for transplantation and potential 
therapies for MS. In vitro studies suggest that neuronal 
stem cells have the potential to restore neuronal activity and 
produce new neurons through transdifferentiation. Adult 
bone marrow-derived stromal cells were shown to induce 
similar immunomodulatory and neuroregenerative effects 
in the animal model of chronic experimental autoimmune 
encephalomyelitis.40,41 These concepts have led to an inter-
est in the use of stem cells for neuronal regeneration and 
restoration of neurologic function in MS. To date, there are 
two clinical trials evaluating the use of autologous stem cells 
for the treatment of MS in humans.42,43
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